These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 22440312)

  • 41. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccination with leishmania hemoglobin receptor-encoding DNA protects against visceral leishmaniasis.
    Guha R; Gupta D; Rastogi R; Vikram R; Krishnamurthy G; Bimal S; Roy S; Mukhopadhyay A
    Sci Transl Med; 2013 Sep; 5(202):202ra121. PubMed ID: 24027025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetically Modified Live Attenuated Leishmania donovani Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice.
    Bhattacharya P; Dey R; Dagur PK; Kruhlak M; Ismail N; Debrabant A; Joshi AB; Akue A; Kukuruga M; Takeda K; Selvapandiyan A; McCoy JP; Nakhasi HL
    Infect Immun; 2015 Oct; 83(10):3800-15. PubMed ID: 26169275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological characterization of rLdTCP1γ for its prophylactic potential against visceral leishmaniasis in hamster model.
    Anand A; Balodi DC; Ramalingam K; Yadav S; Goyal N
    Mol Immunol; 2022 Jan; 141():33-42. PubMed ID: 34798496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).
    Viana KF; Fiuza JA; Gannavaram S; Dey R; Selvapandiyan A; Bartholomeu DC; da Silveira-Lemos D; Bueno LL; Dutra WO; Fujiwara RT; Nakhasi HL; Giunchetti RC
    Parasit Vectors; 2016 Apr; 9():250. PubMed ID: 27136900
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
    Henriquez FL; Campbell SA; Roberts CW; Mullen AB; Burchmore R; Carter KC
    J Parasitol; 2010 Oct; 96(5):929-36. PubMed ID: 20950100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis.
    Agallou M; Smirlis D; Soteriadou KP; Karagouni E
    Vaccine; 2012 Jul; 30(34):5086-93. PubMed ID: 22704924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis.
    Selvapandiyan A; Dey R; Nylen S; Duncan R; Sacks D; Nakhasi HL
    J Immunol; 2009 Aug; 183(3):1813-20. PubMed ID: 19592661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
    Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
    Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.
    Khare P; Jaiswal AK; Tripathi CD; Sundar S; Dube A
    Clin Exp Immunol; 2016 Aug; 185(2):165-79. PubMed ID: 26898994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.
    Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A
    PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-12 enhances Th1-type responses in human Leishmania donovani infections.
    Ghalib HW; Whittle JA; Kubin M; Hashim FA; el-Hassan AM; Grabstein KH; Trinchieri G; Reed SG
    J Immunol; 1995 May; 154(9):4623-9. PubMed ID: 7722314
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Jamal F; Singh MK; Hansa J; Pushpanjali ; Ahmad G; Dikhit MR; Umar MS; Bimal S; Das P; Mujeeb AA; Singh SK; Zubair S; Owais M
    Front Immunol; 2020; 11():817. PubMed ID: 32582140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
    Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.
    Bhowmick S; Ravindran R; Ali N
    BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
    Sarkar K; Das PK
    J Immunol; 1997 Jun; 158(11):5357-65. PubMed ID: 9164956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
    Mazumder S; Maji M; Ali N
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.